Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer.

ABSTRACT:

Objectives

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce heart failure (HF) in at-risk patients and may possess antitumour effects. We examined the effect of SGLT2i on HF and mortality among patients with cancer and diabetes.

Methods

This was a retrospective propensity score-matched cohort study involving adult patients with type 2 diabetes mellitus diagnosed with cancer between January 2010 and December 2021. The primary outcomes were hospitalisation for incident HF and all-cause mortality. The secondary outcomes were serious adverse events associated with SGLT2i.

Results

From a total of 8640 patients, 878 SGLT2i recipients were matched to non-recipients. During a median follow-up of 18.8 months, SGLT2i recipients had a threefold lower rate of hospitalisa

SUBMITTER: Chiang CH 

PROVIDER: S-EPMC10037540 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature